Clinical trial
Zalutumumab in Head and Neck Cancer
NCT00093041 · Genmab, Industry · Completed
Key facts
| NCT number | NCT00093041 |
|---|---|
| Title | Zalutumumab in Head and Neck Cancer |
| Official title | An Open, Single Dose Escalation Study Followed by a Multiple Dose Extension of Anti-EGF Receptor Human Monoclonal Antibody (Zalutumumab) in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Lead sponsor | Genmab, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Head and Neck Neoplasms |
| Intervention type | Drug |
| Interventions | Zalutumumab |
| Enrollment | 28 |
| Start date | Dec 1, 2003 |
| Primary completion | Jan 12, 2005 |
| Completion | Jan 12, 2005 |
| First posted | Oct 1, 2004 |
| Last update posted | Jun 28, 2023 |
| Countries | Denmark, Sweden |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: